These companies use the creative forces of capitalism to solve big problems—and do well by doing good.

Regeneron studies the root causes of diseases and identifies new therapies for rare and ultrarare conditions at its genetics center. For example, the company has been studying conditions such as fibrodysplasia ossificans progressiva (FOP), a disabling disease that transforms muscles, ligaments, and other tissue into bone, and is conducting late-stage trials of a FOP treatment. Regeneron is also testing a novel approach to treating lipodystrophy, a rare disorder that leads to low levels of body fat and its abnormal distribution, plus reduced leptin levels, disrupting metabolism.

Change the World

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

The companies on this year's list stand out for celebrating innovation, promoting cooperation, and more.

GPTW New York Large 2022-Regeneron Pharmaceuticals Inc

Employees say: 
 
“When I joined as a temp, I was made to feel a full member of the team, my suggestions and opinions were appreciated. I also love the willingness by the company to adapt and progress and to provide flexible working arrangements post-COVID. The extra freedom provided by flexible working arrangements has changed the way I view working a 9-5 and has made this company really stand out in a great way.” 
 
Read the Great Place to Work review .

Best Large Workplaces in New York

See which workplaces made this year's list.

Great-Places-to-Work-in-Biotechnology-Large-2022-Regeneron-Pharmaceuticals-Inc_1100602-4

Employees say: 
 
“The culture and energy of the people in Regeneron make it a great place to work. I am proud of our science and ethics. Each employee makes a difference in patients' lives and that is what is truly important. It fuels me to be the best.”

Best Large Workplaces in Biotechnology and Pharmaceuticals

This year’s Fortune 500 marks the 68th running of the list.

This year’s group delivered stellar revenue and profit growth, but it underperformed the broader stock market.

100 Fastest-Growing Companies

Our 2021 list of the 100 best companies to work for, as ranked by their employees. See which companies made the list.

100-best-companies-2021-51-Regeneron

Regeneron’s anti-coronavirus cocktail REGEN-COV was provisionally approved in November 2020 to treat COVID-19 symptoms, and may also reduce its spread. But to develop the important therapy, the biotechnology and pharmaceuticals firm had to keep its own researchers and other staff safe as one of the first U.S. hotspots exploded just miles from its Tarrytown, N.Y., headquarters. The company sent nonessential workers home while implementing safety measures in its research labs. By spring of 2020 Regeneron was providing regular COVID testing for employees, and indefinite paid leave for those infected to recover and quarantine. The firm donated coronavirus-testing components to its home state, with hundreds of staff voluntarily working overtime and weekends to produce them. Regeneron also rolled out a new five-year responsibility strategy organized around stakeholders, including new diversity and inclusion measures after the summer’s wave of protests against anti-Black police brutality. Says one employee: “As an African American male, it’s nice to know that I work for a company that really puts its money where its mouth is regarding making changes in underserved communities.”

Fortune 100 Best Companies to Work For

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-354-Regeneron Pharmaceuticals

The biotechnology company produces medicines and treatments for allergic and inflammatory diseases, eye diseases, cancers, and more. Regeneron became a household name in 2020 when the U.S. government granted it a $450 million federal contract to develop an antibody drug to treat COVID-19. Former U.S. President Donald Trump reportedly received the treatment while hospitalized with the illness in October 2020.

Our 2020 list of the 100 best companies as ranked by their employees. See which companies made the list.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-405-Regeneron

The biopharmaceutical company develops and manufactures medicines designed to treat a range of illnesses, including asthma, chronic pain, cancer, and infectious diseases. In the latter category, Regeneron is deeply involved in the pursuit of treatments for COVID-19.

As we face unprecedented collective challenges, cooperation has become a business superpower.

08.CTW20.Regeneron

The world has battled Ebola since 1976, but only late last year did it get therapies that should meaningfully reduce the virus’s death toll. In a randomized clinical trial conducted during an outbreak in Africa, one such drug—Regeneron’s antibody cocktail, EB3—proved so clearly effective in reducing mortality that the trial was ended early. Regeneron is now racing to develop a comparable cocktail for COVID-19.

Collectively, the ranked companies produced a three-year average shareholder return of 19%, vs. 11% for the S&P 500.

Fastest Growing Companies 2020 90. Regeneron

Our 2019 list of the 100 best companies as ranked by their employees. See which companies made the list.

This year's Fortune 500 marks the 65th running of the list.

Our 2018 list of the 100 best companies as ranked by their employees. See which companies made the list.

This year's Fortune 500 marks the 64th running of the list.

We surveyed tens of thousands of young employees to create this list of millennials’ favorite workplaces.

F500 2018-Regeneron Pharmaceuticals

Employees say: 
 
&nbsp; 
 
"Regeneron is all about innovation. Whether it is in our scientific endeavors, employee recognition programs, or seasonal celebrations we are always finding new and exciting ways to do things." 
 
&nbsp; 
 
"The thing I love most about working at Regeneron is that when they say data is king, they mean it. Our work and projects are always changing based on what the data shows us. This allows us to work as equals with senior management. When you are presenting or discussing projects, it doesn't matter your role— if you have a good idea, and good data to support it, then you are taken seriously. This removes a lot of the bureaucracy and politicking that happens in other companies." 
 
&nbsp;

100 Best Large Workplaces for Millennials

Everybody loves an up-and-comer: 2018's top three-year performers in revenues, profits, and stock returns.

Our 2017 list of the 100 best companies as ranked by their employees. See which companies made the list.

Welcome to the inaugural Fortune Future 50, our new ranking of companies best positioned for breakout growth.

The Future 50

This year's Fortune 500 marks the 63rd running of the list.

Everybody loves an up-and-comer: 2017's top three-year performers in revenues, profits, and stock returns.

Google/Alphabet is the No. 1 place to work for the seventh time in 10 years. Six newcomers include Veterans United at No. 30, Hilton Hotels at No. 56, and Slalom Consulting at No. 100. IKEA’s U.S. arm returns to the list, along with GoDaddy and Sheetz.

This year's Fortune 500 marks the 62nd running of the list.

This year’s list marks Fortune's 18th year of partnering with Great Place to Work. Google ranks No.1 for the sixth time, and 16 new companies make impressive debuts, including Acuity (No. 3), Twitter (No. 24), and Riot Games (No. 13).

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Best Companies

Rank last year

Years on list

U.S. employees

U.S. job openings

Year founded

Perks

100% health coverage

Unlimited sick days

Telecommuting

Job sharing

Subsidized childcare

Compressed work weeks

Fully-paid sabbaticals

On-site fitness/subsidized gym

On-site medical care facility

Non-discrimination policy includes sexual orientation

Sick days for part-timers

College tuition reimbursement

Student loan debt repayment

Hiring/staffing (past 12 Months)

# of job applicants

Avg. # of applicants per opening

# New graduates hired

Fastest-growing Companies

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Current Streak

Years on List

Sector

Company Info

Founded

Industry Vertical

U.S. Employees

Sites

HQ Location

Web Address

Date info provided (companies may opt to keep some data confidential)

Future 50

Overall Score

Industry

Website

Employees

Revenues ($M) (Past 12 Months)

Profits ($M) (Past 12 Months)

Market Value as of Oct. 9, 2019 ($M)

Best Large Workplaces In New York

City

U.S. Revenue

Total Worldwide [including U.S.] Revenue in the Latest Fiscal Year

Strongest Dimension

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Change The World

Impact Segment

Regeneron Pharmaceuticals is a major pharmaceutical company that develops and sells drugs covering areas of immunology, oncology, ophthalmology, and rare diseases. During the COVID-19 outbreak it developed a widely used monoclonal antibody treatment. Other flagship products include Eylea, an injection to treat age-related macular degeneration and other eye conditions; Dupixent, a therapy for inflammatory diseases like atopic dermatitis, asthma, and chronic rhinosinusitis; and Libtayo, for certain types of cancer. The company was incorporated in 1988.

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Regeneron Pharmaceuticals (REGN): Company Profile, Stock Price, News, Rankings

legacy

Regeneron Pharmaceuticals

regeneron pharmaceuticals

Welcome to the Regeneron Pharmaceuticals third quarter 2026 earnings conference call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our third quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron investor relations website shortly after our call concludes. Joining me on today's call are Dr. Leonard Schleifer, Co-Founder, Board Co-Chair, President, and Chief Executive Officer, Dr. George Yancopoulos, Co-Founder, Board Co-Chair, President, and Chief Scientific Officer, Marion McCourt, Executive Vice President, Commercial, and Chris Fenimore, Executive Vice President, Finance, and Chief Financial Officer. For our call today, Len will briefly review key third quarter performance drivers and highlight a few emerging pipeline programs. George will then detail our recent pipeline progress, followed by Marion, who will review our commercial performance, and finally, Chris will discuss our financial results and outlook.

After our prepared remarks, the remaining time will be available for Q&A. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecasting guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement, changes to drug pricing regulations and requirements, and our drug pricing strategy, intellectual property, pending litigation and other proceedings, and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement.

A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30th, 2026, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. In addition, please note that GAAP and non-GAAP financial measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of those measures to GAAP is available in our quarterly results press release and our corporate presentation, both of which can be found on the Regeneron investor relations website. Once our call concludes, the IR team will be available to answer any further questions.

With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer.

Thank you, Ryan, and welcome to everyone joining our call today. We are pleased to report another quarter of strong performance, driven by outstanding commercial execution and a large and diverse pipeline that is continuing to deliver on its promise. Total revenue grew 36%, and non-GAAP earnings per share grew 70% compared to the third quarter of 2025. This marks our third consecutive quarter of double-digit growth on both the top and bottom lines. Our commercial teams continue to execute at a very high level. DUPIXENT, EYLEA HD, and LIBTAYO each set new all-time highs for quarterly net sales for the second quarter in a row. DUPIXENT global net sales in the third quarter, as reported by Sanofi, reached a record $6.5 billion, up 35% year-over-year at constant currency, which is truly remarkable for a medicine approaching 10 years on the market.

In the U.S., where DUPIXENT is the leading biologic in eight of its nine FDA-approved indications, quarterly net sales grew 40% and exceeded $5 billion for the first time, primarily driven by robust demand across all indications, as well as gross-to-net favorability as disclosed by Sanofi. EYLEA HD quarterly net sales in the U.S. reached a new all-time high of approximately $700 million, up 62% from a year ago, and now represent nearly two-thirds of our U.S. retinal franchise. Physician unit demand grew 20% sequentially, reflecting the value retinal specialists and their patients see in extended dosing intervals, as well as last year's label enhancements, which added the retinal vein occlusion indication and greater dosing flexibility. We remain optimistic for approval of the prefilled syringe before the end of the year, and we expect it to drive even further adoption if approved.

LIBTAYO is making important differences for patients with skin and lung cancers, and it continues to build clinical and commercial momentum. In the U.S., it is the leading immunotherapy in non-melanoma skin cancers and the second most prescribed immunotherapy in non-small cell lung cancer. Global net sales reached a record $550 million, up 51% in constant currency, and U.S. net sales grew 81% to nearly $400 million. Last week at ESMO, we presented longer-term data from our phase III C-POST trial, showing an increasing overall survival benefit with adjuvant LIBTAYO in high-risk cutaneous squamous cell carcinoma, where it is the first and only approved immunotherapy. LIBTAYO is now on an annual run rate of approximately $2.2 billion and remains the foundation for our broader oncology strategy. Beyond our strong commercial execution, our pipeline is poised to deliver several potential blockbuster opportunities over the next several years.

Let me highlight new advances in four of our pipeline programs, while George will discuss in more detail, along with other late-stage clinical programs, including Factor XI, LYNOZYFIC, and olatorepatide. In neuromuscular disease, we expect an FDA decision in November for cemdisiran in generalized myasthenia gravis. If approved, cemdisiran would be the first siRNA therapy for generalized myasthenia gravis and the only treatment that can offer quarterly subcutaneous dosing. Early in my career as a neurologist, I cared for many patients with this difficult-to-treat condition, so it is particularly gratifying to see us bring forward a potential new treatment option for them. In metabolic disease, MASH affects millions of people, and treatment options are limited. Our CIDEB program is a great example of our genetics-driven scientific process.

Regeneron Genetics Center discovered that people with naturally occurring loss-of-function variants of the CIDEB gene have a markedly lower risk of fatty liver disease and cirrhosis, which led us to develop a first-in-class siRNA that targets CIDEB. We are encouraged by the initial clinical data, which suggests best-in-class, best-in-disease potential, and we are rapidly advancing this program into registration-enabling studies. I would also like to highlight our program for postural orthostatic tachycardia syndrome, or POTS. This is an increasingly recognized debilitating condition that affects many young people, often disrupting school, work, and daily life, with very few effective treatment options and no FDA-approved medicines. Recent estimates suggest that between 500,000 and several million people in the U.S. alone suffer from POTS.

We believe the initial clinical data that George will highlight supports our antibody's potential to become the first FDA-approved treatment for this disease, and we plan to initiate a potentially pivotal study next year, pending regulatory feedback. In oncology, we recently shared encouraging data for ubamatamab, our MUC16xCD3 bispecific antibody, in advanced low-grade serous ovarian carcinoma. This is a rare and difficult-to-treat form of ovarian cancer that often affects younger women who urgently need better treatment options. We saw durable responses in heavily pre-treated patients at rates well above those historically seen with available therapies. We are already enrolling a dedicated, potentially registrational cohort and plan to start a confirmatory phase III study next year. Each of these programs is supported by compelling clinical data, human genetic validation, or both.

It is no accident that they span four distinct therapeutic areas and that each has first-in-class or best-in-disease potential. That reflects our disease-agnostic enterprise approach to R&D. Rather than confining ourselves to a few therapeutic areas, we apply our core technologies wherever the science leads us. These technology platforms, including our VelocImmune antibody and bispecific engines, Regeneron Genetics Center, and siRNA and gene editing technologies that allow us to translate genetic discoveries like CIDEB into potential medicines. Today, that approach supports approximately 50 clinical programs spanning immunology, oncology, ophthalmology, hematology, cardiovascular and metabolic diseases, neurology, and rare diseases. Our commercial organization has been built the same way. Our teams already call on ophthalmologists, dermatologists, pulmonologists, allergists, gastroenterologists, ENT specialists, oncologists, cardiologists, and hematologists. If cemdisiran is approved, we will begin to call on neurologists as well.

That means many of our pipeline medicines, including several of the programs I just mentioned, can launch into specialties where we already have deep relationships and expertise, and can leverage our existing infrastructure and capabilities. Briefly on business development. Historically, we have been a net out-licensor of innovation, with the most recent example being the expansion of our alliance with Sanofi. We are contributing to the alliance for next-generation long-acting antibodies, all invented at Regeneron, that target the same pathways that made DUPIXENT so successful. Regeneron will lead research and development, and Sanofi will lead global commercialization, now with greater transparency and increased participation by Regeneron. If approved, these medicines can also benefit from DUPIXENT's commercial leadership and the strong market access position it has established, an advantage neither company could capture on its own.

At the same time, our financial strength positions us to bring differentiated external innovation into Regeneron. We have done this effectively to date, primarily through early-stage research collaborations, including those that built our emerging genetic medicines pipeline, of course, siRNA therapeutics, gene therapy, and gene editing. We continue to evaluate a wide range of opportunities, from early clinical programs and platforms to commercial-stage products, with a sharp focus on valuation and strategic fit. In closing, this was an exceptional quarter by every measure. Our three core growth brands are performing at record levels, and our expanded alliance with Sanofi positions us to lead the next era of type 2 inflammation medicines. Our pipeline is poised to deliver additional potential blockbusters across a broad range of diseases, and our commercial organization is built to bring them to patients.

Our future is bright, and we remain focused on translating our science into new medicines that can make a meaningful difference for patients and create long-term value for shareholders. With that, let me turn the call over to George.

Thanks, Len. For my remarks today, I will first provide further details on the four programs that Len highlighted, then cover other key updates from our pipeline. Beginning with our C5 program, regulatory submissions are under review for cemdisiran, our C5 siRNA, for generalized myasthenia gravis, or gMG. An FDA decision is expected next month, and a European Commission decision is anticipated in the second half of 2027. If approved, cemdisiran would be the first and only siRNA therapy approved for gMG. It would be distinguished by a combination of rapid onset, consistent efficacy throughout the dosing interval, manageable safety, and convenient subcutaneous dosing just four times per year. Our C5 program also includes a co-formulation of cemdisiran with pozelimab, our C5 antibody that is already FDA approved for protein-losing enteropathy.

Together, they are being evaluated as a combination therapy for paroxysmal nocturnal hemoglobinuria, or PNH, where we expect to report pivotal results by the end of the year. Initial results from a lead-in cohort of the phase III trial suggest that our novel combination approach could provide best-in-class control of intravascular hemolysis. Our C5 program further includes evaluating cemdisiran with and without pozelimab in geographic atrophy, or GA, via systemic administration. We now expect to report interim 26-week data from an exploratory cohort of our ongoing phase II/III study in early 2027, where we hope to see a trend towards slowing of lesion growth comparable to the approved agents at a similar time point. A potential advantage of our systemic approach is the ability to treat bilateral disease, which affects many patients, while avoiding the potentially devastating ocular safety events seen with certain FDA-approved agents that are delivered intravitreally.

In addition, we are exploring our own intravitreal administration of pozelimab, which might also offer safety advantage over currently approved therapies. Moving to MASH. At the upcoming Liver Meeting in November, we will present first-in-human data for our siRNA for CIDEB. This target was discovered by our Regeneron Genetics Center, which identified CIDEB's unprecedented ability to protect against liver fat and liver disease through our large-scale human genetics database. In the initial data from 40 participants, a single dose was well tolerated and reduced liver fat by approximately 70% on average from baseline in just 12 weeks, bringing mean liver fat to near or below upper limit of normal at every dose level tested. This effect was durable through 24 weeks of follow-up and was accompanied by improvements in liver enzymes, consistent with reduced liver cell injury.

These results not only clinically validate the CIDEB discovery from the Regeneron Genetics Center, but suggest that we have a breakthrough new approach that directly addresses a genetic driver of MASH and could benefit the millions of MASH patients underserved by current approaches. We are working to rapidly advance to registrational trials and look forward to sharing more about this agent at our next Regeneron Roundtable investor event scheduled for November 10th. Moving to postural orthostatic tachycardia syndrome, or POTS. This disease appears to be driven by chronic pathological depletion of intravascular volume. Current treatments include salt and fluid administration, which provide only short-term relief. There are no FDA-approved therapies, and off-label treatments are generally unsatisfactory. At the American Autonomic Society Congress in November, we will be reporting initial results from our phase II study.

After a single treatment with high-dose baloncibart, we saw improvements in the two key endpoints for this disease, tachycardia and orthostatic symptoms, sustained over four weeks from a single dose. These improvements appear to be associated with durable restoration of intravascular volume. We are planning to initiate a potentially registrational study in the first half of next year, pending regulatory feedback, and we believe this could be a game-changing treatment for a debilitating disease with significant unmet need. Next, turning to ubamatamab, our MUC16xCD3 bispecific antibody in development for ovarian cancer, which was featured in a late-breaking plenary session at the International Gynecologic Cancer Society meeting. The data presented there along with additional data, indicate that ubamatamab monotherapy has an approximately 70% objective response rate with prolonged progression-free survival in women with advanced low-grade serous ovarian cancer, with an acceptable safety profile and no biomarker selection required.

To put this in context, chemotherapy and endocrine therapy have historically delivered response rates below 15% in this setting, and the only approved therapy achieved a 44% response rate, but only in the roughly 30% of patients with low-grade serous ovarian cancers who tumor carry a specific biomarker. Based on these encouraging early results for ubamatamab, we are enrolling a potentially registrational cohort and plan to start a confirmatory phase III trial in mid-2027. Turning now to our larger late-stage programs and starting with LYNOZYFIC, our BCMAxCD3 bispecific. We believe LYNOZYFIC is differentiated not only by the efficacy demonstrated in late-line multiple myeloma, but also by our development strategy, which creates important new opportunities in first and second-line settings, and even in pre-malignant disease, with pivotal readouts beginning next year.

In 2027, we expect initial results from our confirmatory trial of LYNOZYFIC monotherapy versus standard of care in patients with multiple myeloma who have received at least one prior line of therapy. In 2028, we expect initial results from our first-line study in transplant-ineligible patients, as well as from our LYNOZYFIC-carfilzomib combination study in patients who have received at least one prior line of therapy. We are also enrolling a potentially registrational cohort in second-line light chain amyloidosis and plan to start a phase III study in first-line light chain amyloidosis by early 2027. In addition, we are actively enrolling a phase III trial in high-risk smoldering myeloma. We also have a differentiated development strategy for odronextamab, our CD20xCD3 bispecific. We have a regulatory application under FDA review for relapse refractory diffuse large B-cell lymphoma, with a February 2027 target action date.

Importantly, we expect results in 2028 from our fully enrolled phase III study of odronextamab monotherapy in first-line follicular lymphoma, which could provide these patients, who have high unmet need, with the first bispecific and chemo-free immunotherapy option. Moving to anticoagulation. For Factor XI inhibition, we continue to favor our antibody approach over small molecules, because antibodies may enable more potent and specific inhibition, with the potential to improve antithrombotic activity without increasing bleeding risk or introducing off-target safety issues. Our program features cenvacibart, our catalytic domain antibody, and amrecibart, our A2 domain antibody. I'm pleased to report that all but one of the planned phase III studies are now enrolling patients. These studies span venous thromboembolism prevention after total knee replacement, stroke prevention in patients with atrial fibrillation, cancer-associated thrombosis, peripheral artery disease, and most recently, venous thromboembolism prevention in patients with peripherally inserted central catheters.

The one remaining phase III study yet to initiate in secondary stroke prevention is expected to begin enrollment by year-end. We expect pivotal results from our knee replacement program starting next year, with other pivotal studies expected to read out in 2028 and beyond. Turning to olatorepatide, our dual GLP-1/GIP receptor agonist, in-licensed from Hansoh. Recently, Hansoh presented encouraging efficacy, safety, and tolerability data from their phase III trial in patients with obesity in China at the European Association for the Study of Diabetes Conference. We look forward to starting our global phase III program, which is differentiated by our ability to co-formulate olatorepatide with PRALUENT, our PCSK9 antibody. We believe this could provide an important new treatment option for the many patients with obesity and type 2 diabetes who comorbidly also suffer from hypercholesterolemia and increased cardiovascular risk.

We plan to begin registrational studies of this combination next year. As Len discussed, we recently announced an expansion of our alliance with Sanofi. Building on the success of DUPIXENT and the validation of the IL-4 and IL-13 pathways as central drivers of type 2 inflammation, the alliance is advancing Regeneron's four fully human, VelocImmune-derived, long-acting antibodies and bispecifics. These candidates are designed to preserve DUPIXENT-like efficacy and safety while enabling substantially less frequent dosing. All four candidates avoid the heavy engineering that tends to compromise biopharmaceutical properties or raise the risk of anti-drug antibodies. Our candidates, which are fully human and non-engineered, also share important molecular properties, so learnings from one should carry over to the others and potentially support an expedited development.

Our first-in-human trial for our lead IL-13 antibody, which has a target dosing interval of every three to six months, is currently enrolling patients with atopic dermatitis, with registrational trials expected to begin in late 2027 and 2028. Three additional programs, a long-acting IL-4/IL-13 bispecific, a long-acting antibody to IL-4 receptor alpha, and an IL-4 ligand antibody, are expected to enter the clinic next year. Relevant to these programs, I want to end by reminding you that we have previously shared early clinical results for our BCMAxCD3 bispecific in combination with DUPIXENT in severe food allergy. These results strongly supported our hypothesis that food allergies could potentially be cured by rapidly and completely depleting plasma cells, which produce immunoglobulins, including the allergy-causing IgEs, and then continuously suppressing the return of IgE antibodies by blocking IL-4 and IL-13.

While the BCMAxCD3 eliminates plasma cells producing all classes of immunoglobulins, we have invented a new bispecific antibody that selectively eliminates only the IgE-producing and allergy-causing plasma cells. We plan to build on our groundbreaking results combining our BCMA bispecific with DUPIXENT by expeditiously pursuing this more targeted approach, with clinical studies of this new bispecific antibodies to start in the first half of 2027. In summary, we have strong momentum across our broad and diverse pipeline that we believe has the potential to change the practice of medicine across many diseases with high unmet need. With that, let me turn it over to Marion.

Thank you, George. Our third quarter results reflect strong commercial execution across our portfolio, with our largest brands achieving new all-time highs in net sales. Our team is also focused on recent and upcoming launches, with PASATRU now approved in the U.S. for ultra-rare FOP, and we are preparing for the November PDUFA for cemdisiran in generalized myasthenia gravis. Starting with DUPIXENT, which continues to deliver transformative benefits to patients across nine type 2 inflammatory diseases, with more than 1.5 million patients currently treated worldwide. In the U.S., DUPIXENT remains the most prescribed branded biologic among dermatologists, pulmonologists, allergists, and ENTs. Third quarter worldwide net sales exceeded $6.5 billion, reflecting 35% growth on a constant currency basis. U.S. net sales grew 40% year-over-year to $5.1 billion, driven by continued growth across all indications and age groups, as well as favorable gross-to-net adjustments as reported by Sanofi.

DUPIXENT is the leading biologic across our blockbuster indications of atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis, reported by its best-in-class clinical efficacy and safety profile. Uptake is also strong in our more recently launched indications of COPD, prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis, with continued growth in new-to-brand prescriptions. With significant opportunity for future growth across all nine indications, DUPIXENT is well-positioned over both the near and long term. Additionally, we are excited about the recently announced expansion of the Regeneron-Sanofi alliance, and to continue building on the strong foundation we've laid together with DUPIXENT. Turning to our retinal franchise, in the third quarter, combined EYLEA HD and EYLEA U.S. net sales were $1.1 billion, down 1% compared to last year, with EYLEA HD now comprising nearly two-thirds of the franchise net sales.

Third quarter EYLEA HD net sales in the U.S. were $699 million, up 62% versus prior year. These results demonstrate strong physician unit demand, which grew 20% from the second quarter. This growth is driven by the ongoing benefit of recent label enhancements, which have increased adoption and broadened use of EYLEA HD across the spectrum of retinal practices. Physicians increasingly recognize EYLEA HD as the best-in-class product in the anti-VEGF category based on its efficacy, safety, and durability. EYLEA U.S. net sales were $400 million for the quarter, a 41% decrease versus the prior year. Sequential physician unit demand declined by a high single-digit percentage compared to the second quarter, with this decline partially offset by favorable gross-to-net adjustments. Both EYLEA HD and EYLEA benefited modestly from the timing of end-of-quarter shipments.

Looking ahead to the fourth quarter, we expect continued EYLEA HD momentum, with sequential physician unit demand growth of approximately 10%, partially offset by ongoing pricing pressure, resulting in full-year net sales growth of over 50% compared with 2025. For EYLEA, we expect a sequential demand decline in the low to mid-teens in the fourth quarter. Overall, the franchise remains in a strong position despite increasing competition from additional aflibercept 2 mg biosimilar launches, and we look forward to potential FDA approval of the EYLEA HD prefilled syringe to help sustain EYLEA HD momentum in 2027 and beyond. Turning to LIBTAYO, which delivered worldwide net sales of $550 million, up 51% year-over-year on a constant currency basis. In the U.S., net sales were $396 million, up 81%. In non-melanoma skin cancer, LIBTAYO continues its strong trajectory as the leading immunotherapy.

In the U.S., the recent approval in adjuvant CSCC is helping to drive growth and is changing the treatment paradigm. LIBTAYO remains the only NCCN Category 1 preferred immunotherapy option for eligible patients, and ongoing formulary wins are driving increased usage. In non-small cell lung cancer, LIBTAYO remains the second most prescribed immunotherapy as physicians increasingly recognize its strong clinical profile. We continue to build on LIBTAYO's strong momentum by enhancing the patient experience through extended dosing and shorter infusion times across all approved indications. We recently received a positive CHMP opinion for every six-week dosing for LIBTAYO, along with an infusion time as short as 15 minutes. An sBLA for this updated dosing regimen is under review with the FDA, with a decision expected by March 2027. We expect continued growth for LIBTAYO as we gain incremental share in lung cancer and drive uptake in adjuvant CSCC.

Onto LYNOZYFIC in multiple myeloma, physician feedback on the currently approved late-line setting remains positive based on LYNOZYFIC's differentiating efficacy and safety profiles, lower hospitalization requirements, and convenient dosing. Despite its strong profile, we expect LYNOZYFIC growth to remain modest as we work to advance into earlier lines of therapy. We are also building Regeneron's rare disease portfolio, serving patients with significant unmet need. EVKEEZA continues to grow in its sixth year on the market, with U.S. net sales of $55 million, up 28% versus the prior year. We have also expanded our portfolio with the recent launches of OTARMENI for genetic hearing loss and PASATRU for FOP. Initial progress for both brands is promising, and we look forward to helping patients suffering from these devastating diseases. Finally, in neurology, we are preparing for the potential launch of cemdisiran in generalized myasthenia gravis, which has a November PDUFA date.

We see significant commercial opportunity for cemdisiran based on three key factors: its novel siRNA modality, rapid onset and durable efficacy without the waning treatment effect observed with many other approved therapies, and convenient four-times-per-year subcutaneous dosing. In closing, our third quarter results reflect strong commercial capability across therapeutic areas. We have built an effective commercial infrastructure that enables us to execute across both inline brands and new launches. As Len mentioned earlier, our commercialization platform currently spans nearly every relevant specialty, and this market experience positions us well for the many potential new products from our pipeline. Whether a common or rare disease medicine, specialty or internal medicine prescriber, medical or pharmacy benefit product, we are confident in the capabilities of our commercial organization in both the near and longer term. With that, I will turn over to Chris.

Thank you, Marion. My comments today on Regeneron's financial results and outlook will be on a non-GAAP basis unless otherwise noted. Regeneron delivered a strong third quarter, once again reaching double-digit growth on both the top and bottom line, driven by some sustained momentum across our key growth drivers and solid execution throughout the business. Third quarter total revenue increased 36% from the prior year to $5.1 billion, driven primarily by higher Sanofi collaboration revenue, along with strong growth from both LIBTAYO and EYLEA HD. Third quarter diluted net income per share grew 70% to $20.07 on net income of $2.2 billion. Beginning with the Sanofi collaboration, third quarter collaboration revenues reached an all-time high of $2.7 billion, including $2.6 billion from our share of collaboration profits.

Our share of profits increased 77% versus the prior year, primarily driven by continued DUPIXENT net sales growth and the repayment of the Sanofi development balance, which was completed in the second quarter. Consequently, in the third quarter, we recorded our full share of collaboration profits for the first time. Under the recently amended antibody collaboration, Regeneron and Sanofi will share equally the development and commercialization costs of four next-generation antibodies. Since R&D costs will be co-funded as they are incurred, there will be no R&D development balance. Global profits from these antibodies will also be shared 50/50, while the existing economic terms for DUPIXENT and KEVZARA remain unchanged. Regeneron expects to record the full $1 billion upfront payment as Sanofi collaboration revenue in the fourth quarter, with any future milestone payments recognized in full in the period achieved. Moving to Bayer.

Third quarter net sales of EYLEA 8 mg and EYLEA outside the U.S. were $643 million, inclusive of $384 million of EYLEA 8 mg sales. Total Bayer collaboration revenue was $267 million, of which $212 million related to our share of net profits outside the U.S. Other revenues in the third quarter increased 57% year-over-year to $310 million, including $253 million from our share of ARCALYST profits and ILARIS royalties. Third quarter ILARIS royalty revenue included an approximately $60 million cumulative catch-up adjustment reflecting the application of the highest royalty tier on year-to-date sales. This cumulative catch-up will not recur in the fourth quarter. Now to our operating expenses. Third quarter R&D expense was $1.7 billion, driven by continued advancement of our broad clinical pipeline, as well as the timing of related clinical manufacturing.

Third quarter SG&A was $588 million, an increase of 9% year-over-year, reflecting investments across our commercial organization and broader business. Our third quarter effective tax rate was 15%. The year-over-year increase was primarily due to a shift in the geographic mix of our pre-tax income, driven by higher Sanofi collaboration revenue. Regeneron generated $2.9 billion of free cash flow through the first nine months of 2026, and ended the quarter with $16.2 billion of cash and marketable securities net of debt. In the first nine months of 2026, we deployed nearly $3 billion across share repurchases, business development, and dividends. This included $2.3 billion to repurchase 3.2 million shares. We expect full-year share repurchases to total approximately $3 billion, and as of September 30th, we had $2.2 billion remaining under our repurchase authorization. Moving to guidance.

We made modest refinements to our 2026 financial guidance as we enter the last quarter of the year. A full summary of our guidance can be found in our earnings press release published earlier this morning. As we look to 2027, Len and George discussed the meaningful progress we are making across our innovative pipeline. We expect to advance multiple large registrational programs in myeloma, anticoagulation, obesity, and emerging mid-stage opportunities with significant revenue potential, such as our programs in POTS and MASH. This year alone, we are on pace to initiate more than 15 phase III trials. We believe these investments can create substantial long-term value. To support this progress, we currently expect 2027 R&D expense to increase by a mid-teens percentage compared with 2026.

Regarding our 2027 effective tax rate, we expect approximately 100 basis points-200 basis points of upward pressure relative to 2026, consistent with our prior long-term tax rate commentary. Finally, turning to the new BARDA agreement for INMAZEB. Beginning in late 2027, we expect to supply additional treatment doses to the U.S. government through 2031. Therefore, we do not anticipate recording any revenue in the fourth quarter of 2026 for INMAZEB. In conclusion, we delivered another outstanding quarter and remain well-positioned to invest in our differentiated pipeline, deliver important medicines to patients, and create durable long-term value for shareholders. With that, I'll pass the call back to Ryan.

Chris, this concludes our prepared remarks. We will now open up the call for Q&A. To ensure we are able to address as many questions as possible, we will answer one question from each caller before moving to the next. Shannon, can we please go to our first question?

Thank you. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Our first question comes from the line of Salveen Richter with Goldman Sachs. Your line is now open.

Hey, good morning. Thank you for taking our question. This is Elizabeth Webster on for Salveen. Just ahead of AASLD, could you further frame the clinical data from CIDEB we've seen to date in the context of the competitive landscape and expand upon where Regeneron would position this asset? In your view, what are the key aspects of differentiation? Also noting you will speak about this at the roundtable, but any color you can share now would be appreciated. Thank you.

Well, the other approaches to MASH and reducing liver fat are all somewhat indirect in that they are not directly addressing the fundamental genetic pathway that's underlying or driving this disease. They work, for example, by trying to decrease body weight. For example, semaglutide, a GLP, which lowers body weight, which then indirectly lowers liver fat. Similarly, the product from Madrigal works by a separate mechanism as well. This is the first pathway that directly involves a genetically validated target that is central to protecting the liver against multiple liver diseases, including liver fat-generated diseases. Reflecting the genetics and the specificity and importance of this pathway, the liver fat reductions that one is seeing here are unprecedented in the rapidity of onset and the depth of the liver fat reductions. As we said, they're on the order of 70% achieved in just a few weeks.

And this is with a single dose lasting for a very long period of time. These are really game-changing results and, of course, highly supported with the genetics. So, of course, we've reproduced now the genetic effects on liver fat. This gives us even more confidence that we're going to reproduce the genetic effects on benefits in terms of liver disease. So, this is really game-changing, unprecedented. There's nothing like this before for this disease, and I think it's reflective of our approach to using large-scale human genetics to actually define the underlying mechanism of disease and not just come up with drugs that sort of accidentally or by chance also benefit a disease of interest, but actually defining the underlying genetic pathway causing the disease, directly targeting with one of our signature platforms, in this case, the siRNA approach, and producing unprecedented results in these early-stage data.

Thanks, George, and we certainly look forward to highlighting that in a couple weeks at our Regeneron Roundtable event on November 10th. Shannon, let's move to the next question, please.

Our next question comes from the line of Brian Abrahams with RBC Capital Markets. Your line is now open.

Hey, guys. Good morning. Thanks so much for taking my question here. Wonder if you could talk a little bit more about the cemdisiran pre-launch activities, just kind of some of the learnings there as you prepare for the launch, now that you're closer to the approval and a potential label, and just how you're thinking about the initial target audience and uptake. Thanks.

Sure. Very happy to make comments. We certainly have a very talented neurology team at Regeneron. Very pleased with the caliber, experience that the team has in neurology with other programs, and now we are really excited to bring that to Regeneron. As we mentioned, PDUFA date in November, very exciting, so launch activities preparation are well underway. I am not going to say a lot about launch strategy, but delighted to talk about it in the future. I am certainly sure everyone that we are launch-ready. We look forward to the label and certainly bringing cemdisiran into the marketplace as a really important enhancement for patients who need this treatment.

Thanks, Marion. Let's move to the next question, Shannon.

Our next question comes from the line of Akash Tewari with Jefferies. Your line is now open.

Hey, thanks so much. I noticed that your Sanofi collaboration allows you to add another early-stage Sanofi asset. Can we revisit STAT6? If the STAT6 oral start to deliver efficacy, not better, but let's just say similar to DUPIXENT, would that be an asset that your team would be interested in adding to the ongoing collaboration with Sanofi? Thank you.

Regeneron Pharmaceuticals (REGN) Q3 2026 Earnings Call Transcript

Company Participants